| Symbol | LTRN |
|---|---|
| Name | LANTERN PHARMA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1920 MCKINNEY AVENUE,7TH FLOOR, DALLAS, Texas, 75201, United States |
| Telephone | +1 972 277-1136 |
| Fax | — |
| — | |
| Website | https://www.lanternpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001763950 |
| Description | Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firms pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Additional info from NASDAQ: |
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Read more(90% Positive) LANTERN PHARMA INC. (LTRN) Announces Enrollment Update for million Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Read moreNew Form SCHEDULE 13D/A - Lantern Pharma Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001813314-26-000008 <b>Size:</b> 39 KB
Read moreDirector Schalop Lee Troy 🟡 adjusted position in 0 shares (1 derivative) of Lantern Pharma Inc. (LTRN) at $2.27 Transaction Date: May 12, 2026 | Filing ID: 023083
Read moreDirector KEYSER D JEFFREY 🟡 adjusted position in 0 shares (1 derivative) of Lantern Pharma Inc. (LTRN) at $2.27 Transaction Date: May 12, 2026 | Filing ID: 023082
Read moreLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Read moreNew Form 424B5 - Lantern Pharma Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001493152-26-022895 <b>Size:</b> 533 KB
Read moreLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2023-06-09 | 2026-07-28 | ClinicalTrials.gov |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advance… | Phase2 | Adenocarcinoma of Lung | Recruiting | 2023-03-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients Wit… | Phase1 | Relapsed or Refractory Lymphomas | Recruiting | 2023-01-03 | 2028-11-30 | ClinicalTrials.gov |
| NCT03643107 | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Resp… | Phase2 | Metastatic Castration-Resistant Prostate Cancer Patients | Completed | 2018-10-17 | 2022-08-01 | ClinicalTrials.gov |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Re… | Phase3 | Non-small Cell Lung Cancer | Completed | 2010-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00039780 | Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast … | Phase3 | Breast Neoplasms | Completed | 2001-09-01 | 2014-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Placebo | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| Placebo | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| Prednisolone 10 mg | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |
| Irofulven | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Spironolactone | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Placebo | DRUG | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | DRUG | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| LP-284 | DRUG | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Olaparib | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Spironolactone | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-184 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Carboplatin | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Irofulven | DRUG | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |